A
Alan I. Green
Researcher at Dartmouth College
Publications - 175
Citations - 11830
Alan I. Green is an academic researcher from Dartmouth College. The author has contributed to research in topics: Schizophrenia & Clozapine. The author has an hindex of 52, co-authored 174 publications receiving 11013 citations. Previous affiliations of Alan I. Green include Johns Hopkins University School of Medicine & Icahn School of Medicine at Mount Sinai.
Papers
More filters
Journal ArticleDOI
Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia
Susan Whitfield-Gabrieli,Heidi W. Thermenos,Snezana Milanovic,Ming T. Tsuang,Stephen V. Faraone,Robert W. McCarley,Martha E. Shenton,Alan I. Green,Alfonso Nieto-Castanon,Peter S. LaViolette,Joanne Wojcik,John D. E. Gabrieli,Larry J. Seidman +12 more
TL;DR: Among patients, the magnitude of MPFC task suppression negatively correlated with default connectivity, suggesting an association between the hyperactivation and hyperconnectivity in schizophrenia.
Journal ArticleDOI
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).
Herbert Y. Meltzer,Larry Alphs,Alan I. Green,A. Carlo Altamura,Ravi Anand,Alberto Bertoldi,Marc Bourgeois,Guy Chouinard,M. Zahur Islam,John M. Kane,Ranga Krishnan,Jean-Pierre Lindenmayer,Steven G. Potkin,Saide Altinsan,Siemion Altman,Likiana Avigo,Richard Balon,Vanda Benešová,Luis Bengochea,István Bitter,Elisabeth Bokowska,Bernardo Carpiniello,Daniel E. Casey,Giovanni B. Cassano,James C.-Y. Chou,Libor Chvila,Jean Dalery,Pedro L. Delgado,Liliana Dell'Osso,Carl Eisdorfer,Robin Emsley,Dawn Eng,Tom A. Fahy,Vera Folnegovic,Sophie Frangou,Pedro Gargoloff,Alberto Giannelli,Ira D. Glick,Richard Greenberg,George T. Grossberg,Doris Gundersen,Hannale Heila,George Hsu,Naveed Iqbal,Miro Jakovljević,Richard C. Josiassen,Akos Kassaifarkas,Robert Kerwin,Frederic Khidichian,Mary Ann Knesevich,Jack S. Krasuski,Vinod Kumar,Veronica W. Larach,Michael D. Lesem,Shôn Lewis,Pierre-Michel Llorca,H. Edward Logue,Stephen Martin,Muriel Maurel-Raymondet,Laszlo Mod,Eva Morik,Carlos Morra,Ann M. Mortimer,Mojtaba Noursalehi,Gyorgy Ostorharics-Horvath,Ivo Paclt,Jörg Pahl,Linda Pestreich,J. L. Peters,Rosario Pioli,Michael G. Plopper,Thomas Posever,Mark Hyman Rapaport,Delbert Robinson,Carlo Andrea Robotti,Harry Rohme,Frédéric Rouillon,David A. Sack,Isaac Sakinsofsky,Phillip Seibel,George M. Simpson,Nancy Temkin,Oladapo Tomori,Santha Vaidain,Zdeòka Vyhnándová,Frederick Young,Daniel L. Zimbroff,Marie Agathe Zimmerman +87 more
TL;DR: It is suggested that clozapine therapy significantly reduces suicidal behavior in patients with schizophrenia and schizoaffective disorder at high risk for suicide, and use of clozAPine in this population should lead to a significant reduction in suicidal behavior.
Journal ArticleDOI
Antipsychotic drug effects on brain morphology in first-episode psychosis
Jeffrey A. Lieberman,Jeffrey A. Lieberman,Gary D. Tollefson,Cecil Charles,Robert B. Zipursky,Tonmoy Sharma,René S. Kahn,Richard S.E. Keefe,Alan I. Green,Raquel E. Gur,Joseph P. McEvoy,Diana O. Perkins,Robert M. Hamer,Hongbin Gu,Mauricio Tohen,Mauricio Tohen +15 more
TL;DR: In this article, the authors found that olanzapine-treated patients have less change over time in whole brain gray matter volumes and lateral ventricle volumes than haloperidol-treatment patients and that gray matter changes are associated with changes in psychopathology and neurocognition.
Journal ArticleDOI
Comparative Efficacy and Safety of Atypical and Conventional Antipsychotic Drugs in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Haloperidol
Jeffrey A. Lieberman,Gary D. Tollefson,Mauricio Tohen,Alan I. Green,Raquel E. Gur,René S. Kahn,Joseph P. McEvoy,Diana O. Perkins,Tonmoy Sharma,Robert B. Zipursky,Hank Wei,Robert M. Hamer +11 more
TL;DR: Both olanzapine and haloperidol were effective in the acute reduction of psychopathological symptoms in this group of patients with first-episode psychosis, and olanZapine had several relative advantages in therapeutic response.
Journal ArticleDOI
The Effects of Clozapine on Alcohol and Drug Use Disorders Among Patients With Schizophrenia
TL;DR: The use of clozapine by patients with co-occurring substance disorders deserves further study in randomized clinical trials because of the small number of patients with drug use disorders.